Skip to main content

COR

Stock
Health Care
Medical Distribution

Performance overview

COR Price
Price Chart

Forward-looking statistics

Beta
0.35
Risk
18.21%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Company info

SectorHealth Care
IndustryMedical Distribution
Employees29K
Market cap$46.4B

Fundamentals

Enterprise value$66.1B
Revenue$310.2B
Revenue per employee—
Profit margin0.55%
Debt to equity827.73

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$8.65
Dividend per share$2.20
Revenue per share$1,586.71
Avg trading volume (30 day)$393M
Avg trading volume (10 day)$459M
Put-call ratio—

Macro factor sensitivity

Growth+2.5
Credit+0.6
Liquidity+0.1
Inflation-0.7
Commodities+0.4
Interest Rates-0.5

Valuation

Dividend yield0.74%
PEG Ratio18.11
Price to sales0.19
P/E Ratio18.11
Enterprise Value to Revenue0.21
Price to book56.67

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend dayMay 16, 2025

News

Corn Crash Or Sugar Rush? ETFs React To Trump's Sweet Talk On Coca-Cola

A seemingly offhand comment by President Donald Trump may have caused more than political rumination; it's now causing turmoil in commodity markets, with impacts for ETF investors.

Benzinga (July 18, 2025)
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer

CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.

Zacks Investment Research (July 15, 2025)
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research (July 11, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free